In the STEP-HFpEF Trial, which involved patients with HFpEF and obesity, exercise capacity was significantly improved in those receiving the GLP-1 receptor agonist semaglutide compared to those receiving a placebo over a period of 52 weeks [168]. This evidence concerns the gene GLP1R and obesity disorder.